Navigation Links
Experimental drug shows promise in advanced kidney cancer
Date:9/26/2007

Barcelona, Spain: A new drug has shown promise in patients with advanced kidney cancer whose options run out after their tumour fails to respond to the cutting edge therapy.

The study, presented today (Wednesday) at the European Cancer Conference (ECCO 14) in Barcelona, showed that the experimental drug, axitinib, shrank tumours and delayed progression of the disease in a group of patients who are among the toughest to treat.

In the study, scientists gave axitinib to 62 patients whose kidney cancer had spread and who had not benefited from a standard treatment, sorafenib, a targeted therapy designed to disrupt cell division signals in cancer cells and block the tumours ability to form new blood vessels that help it grow. Fourteen of the patients also had been given to no avail another similarly targeted drug, sunitinib, after the sorafenib had failed to work. Axitinib works similarly to the other two but is believed to be more potent.

More than half the patients 51 percent experienced tumour shrinkage and in 23 percent of them the shrinkage is considered significant, said lead investigator Dr Brian I. Rini, an associate professor of medicine at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, USA, and a paid member of the Pfizer scientific advisory board. Preliminary analysis shows the progression-free survival was on average more than 7.7 months. We think these results are impressive because these patients were heavily pre-treated and with drugs thought to be similar to axitinib.

The disease progressed in only 24 percent of patients, which we think is low in this kind of setting, Rini added. The study found the tumour remained stable in 37 percent of the patients.

Historically, metastatic kidney cancer has been very tough to treat, with a median survival of 12 months. Through the results of this trial, it appears that axitinib is a very active drug in renal cell cancer that can benefit a large number of patients, Rini added.

The drugs maker, Pfizer, paid for the study. Axitinib is also being tested in advanced pancreatic, thyroid, lung and breast cancers.


'/>"/>

Contact: Emma Ross
rosswrite@mac.com
34-932-308-832
ECCO-the European CanCer Conference
Source:Eurekalert

Related medicine news :

1. Experimental treatment for Ebola Virus Shows promising results in mice
2. FDA approves Phase 0 trial which tests experimental drugs on humans
3. Experimental drug to fight flu
4. Experimental SARS Vaccine
5. Experimental vaccine for shingles is effective
6. Experimental Blood Test May Spot Heart Attack Risk, Study Says
7. Five AIDS Patients To Receive Experimental Anti-retroviral Drugs
8. TMC 114 and 125 experimental drugs to be tested on four HIV patients
9. Protection against HIV and Herpes is possible with the Experimental Microbicide
10. Experimental Therapy Effective Against Malignant Melanoma in Horses
11. Experimental Alzheimer’s Drug curbs the disease in mic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... 2017 , ... The American Academy of Thermology ... healthcare training and clinical application of medical infrared imaging, has announced the dates ... Courses for Technicians, respectively. , For the first time the AAT is offering ...
(Date:1/23/2017)... ... January 23, 2017 , ... METTLER TOLEDO has announced ... by Applying Simple PAT Tools . , Crystallization is a common ... desired product. Chemists now spend more time developing better intermediate and final ...
(Date:1/23/2017)... ... January 23, 2017 , ... Steviva Ingredients, ... certification under the USDA National Organic Program (NOP) for its Portland SQF Level ... established organic production and handling systems to complement our current rigorous food-safety management ...
(Date:1/23/2017)... ... January 23, 2017 , ... Old School Labs™, makers of the wildly ... Physique bodybuilder Breon Ansley to its growing team of brand ambassadors. The Olympia top ... and in less than a year was able to turn professional, participating in the ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... providing high-quality general gynecological care and gynecological services for women of ... personalized care for a wide variety of reproductive services from routine health screenings ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... GREENWICH, Connecticut , January 24, 2017 ... Gemeinschaftsprojekts mit dem Molecular Surgical Laboratory des Massachusetts General ... angekündigt. Dabei geht es um die Identifizierung und ... von innovativen Ansätzen, dass sie der Resistenz von Antibiotika ... ...
(Date:1/24/2017)... 23, 2017 Optoelectronic components have the ... The interaction of these components with light makes ... range of applications. These components are primarily used ... and healthcare among others. Growing application ... low power consumption, reliability, scalability, and performance is ...
(Date:1/24/2017)... , Jan. 23, 2017 INTRODUCTION ... way from conventional syringes with vials to prefilled ... These modern devices have become preferred devices for ... prefilled syringes has been rising strongly over the ... facilities are now adopting this format for delivering ...
Breaking Medicine Technology: